Search results for "1003"

showing 10 items of 74 documents

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

2014

BRAF-V600E expression is identified in hematopoietic progenitor and precursor myeloid dendritic cells in patients with high-risk LCH, and enforced expression of BRAF-V600E in CD11c+ cells recapitulates a high-risk LCH-like phenotype in mice.

MalePathologyendocrine system diseasesCellular differentiationCD34Antigens CD34Mice0302 clinical medicineLangerhans cell histiocytosisBone MarrowRisk FactorsImmunology and Allergyskin and connective tissue diseasesChild0303 health sciencesCell Differentiation3. Good healthHistiocytosismedicine.anatomical_structurePhenotypeTreatment Outcome030220 oncology & carcinogenesisChild PreschoolAntigens Surface2723 Immunology and AllergyFemaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyImmunologyCD11c610 Medicine & healthBiologyArticle03 medical and health sciencesGermline mutationmedicineAnimalsHumansCell LineageGenetic Predisposition to DiseaseLectins C-TypeProgenitor cellneoplasms030304 developmental biology2403 ImmunologyHistocompatibility Antigens Class II302InfantCorrectionDendritic Cellsmedicine.diseaseHematopoietic Stem Cellsdigestive system diseasesCD11c Antigenenzymes and coenzymes (carbohydrates)Histiocytosis Langerhans-CellMannose-Binding Lectins10032 Clinic for Oncology and HematologyMutationBone marrowThe Journal of experimental medicine
researchProduct

Venous thromboembolism in patients hospitalized for hip joint replacement surgery

2020

Venous thromboembolism (VTE) is a potentially life-threatening disease. Major transient risk factors include trauma, surgery, and immobilization. Patients undergoing hip joint replacement (HJR) are characterized by a high risk of postoperative VTE, but data on the time trends of VTE rates in this population are sparse.In an analysis of the German nationwide inpatient sample, we included all hospitalizations for elective primary HJR in Germany from 2005 to 2016. Time trends of the surgical procedure, overall death rates, and VTE rates were analysed, and predictors of VTE identified.Overall, 1,885,839 inpatients with elective primary HJR (59.1% women, 51.4% ≥70 years) were included in the ana…

Malemedicine.medical_specialtyArthroplasty Replacement HipPopulation2720 Hematology610 Medicine & healthDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsHip replacementGermanymedicineHumanscardiovascular diseasesHospital Mortalityeducationeducation.field_of_studybusiness.industryMortality rate10031 Clinic for AngiologyCancerPerioperativeVenous ThromboembolismHematologyequipment and suppliesmedicine.diseaseSurgeryPulmonary embolismHospitalization030220 oncology & carcinogenesisFemalebusinessVenous thromboembolism
researchProduct

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baselin…

2021

Abstract Introduction Sex and the presence of specific provoking risk factors, along with age, influence the presentation and prognosis of venous thromboembolism (VTE). We investigated the presentation, course and quality of life in women and men with acute VTE classified according to their VTE provoking factors. Methods PREFER in VTE is an international, non-interventional registry of patients with a first episode of acute symptomatic VTE. Baseline provoking factors were classified as follows: major transient, minor transient, active cancer, and none identifiable. The primary outcome was recurrent VTE. Quality of life and treatment satisfaction were secondary outcomes. Results Of 3,455 pat…

Malemedicine.medical_specialtyEpidemiology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceInternal medicineDeep vein thrombosisEpidemiologyInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineFirst episodeSex Characteristicsbusiness.industry10031 Clinic for AngiologyAbsolute risk reductionCancerAnticoagulantsVenous Thromboembolismequipment and suppliesmedicine.diseaseSex specificNeoplasm RecurrenceRisk factorsLocal2724 Internal MedicineQuality of LifeSexFemalePresentation (obstetrics)Neoplasm Recurrence LocalbusinessVenous thromboembolism
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry.

2020

Abstract Lemierre syndrome is a rare but potentially fatal condition characterized by septic thrombophlebitis of the head and neck district, preferentially affecting adolescents and young adults and manifesting as a complication of a local bacterial infection – typically, a pharyngotonsillitis or an abscess. It is historically associated with the Gram-negative anaerobic rod Fusobacterium necrophorum and with thrombophlebitis of the internal jugular vein. However, its definition has never been firmly established, and its spectrum within the continuum of bacteria-associated thrombophlebitis may be larger than what presumed so far. Recent evidence suggests that its prognosis remains serious ev…

medicine.medical_specialtyAdolescent2720 Hematologyved/biology.organism_classification_rank.species610 Medicine & health030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciencesYoung Adult0302 clinical medicineDisease registryFusobacterium necrophorumEpidemiologymedicineHumansSeptic thrombophlebitisRegistriesAbscessIntensive care medicinebiologyved/biologybusiness.industry10031 Clinic for AngiologyHematologyLemierre SyndromeThrombophlebitisbiology.organism_classificationmedicine.diseasePharyngitisAnti-Bacterial AgentsFusobacterium necrophorumFusobacterium030220 oncology & carcinogenesismedicine.symptomJugular VeinsbusinessThrombosis research
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

D-dimer testing after anticoagulant discontinuation to predict recurrent venous thromboembolism

2021

medicine.medical_specialtymedicine.drug_classbusiness.industry10031 Clinic for AngiologyAnticoagulantMEDLINEAnticoagulants610 Medicine & healthVenous ThromboembolismGastroenterologyDiscontinuationFibrin Fibrinogen Degradation ProductsRecurrenceRisk Factors2724 Internal MedicineInternal medicineD-dimerInternal MedicinemedicineHumansbusinessVenous thromboembolismEuropean Journal of Internal Medicine
researchProduct

Variable pulmonary manifestations in Chitayat syndrome: Six additional affected individuals

2020

Hand hyperphalangism leading to shortened index fingers with ulnar deviation, hallux valgus, mild facial dysmorphism and respiratory compromise requiring assisted ventilation are the key features of Chitayat syndrome. This condition results from the recurrent heterozygous missense variant NM_006494.2:c.266A>G; p.(Tyr89Cys) in ERF on chromosome 19q13.2, encoding the ETS2 repressor factor (ERF) protein. The pathomechanism of Chitayat syndrome is unknown. To date, seven individuals with Chitayat syndrome and the recurrent pathogenic ERF variant have been reported in the literature. Here, we describe six additional individuals, among them only one presenting with a history of assisted ventil…

Adultbronchomalacia2716 Genetics (clinical)hyperphalangismPediatricsmedicine.medical_specialtyAdolescent10039 Institute of Medical Genetics610610 Medicine & healthChitayat syndromeFingersYoung Adult03 medical and health sciences1311 Geneticsrespiratory distressExome SequencingGeneticsmedicineHumansMissense mutationGenetic Predisposition to DiseaseHallux ValgusRespiratory systemChildGenetics (clinical)030304 developmental biologyCHITAYAT SYNDROME0303 health sciencesPierre Robin SyndromebiologyRespiratory distressbusiness.industry030305 genetics & heredityFaciesmedicine.diseasebiology.organism_classificationPhenotype3. Good healthRepressor ProteinsValgusERFChild Preschoolulnar deviation570 Life sciences; biologyFemaleUlnar deviationBronchomalaciabusinessAmerican Journal of Medical Genetics Part A
researchProduct